Former Juno Exec Stern Joins FogPharma as Chief Scientific Officer

FogPharma has appointed Howard Stern to serve as its chief scientific officer. Before joining the Boston company, Stern was vice president of translational sciences at Juno Therapeutics, which was acquired by Celgene (NASDAQ: [[ticker:CELG]]) in 2015. Stern’s experience also includes posts at Infinity Pharmaceuticals and Genentech. In other moves, FogPharma named Peter Fekkes vice president of discovery bioscience. He joins the company from HotSpot Therapeutics. Nearly a year ago, FogPharma raised $66 million in Series B funding to support development of “cell-penetrating miniprotein” drugs.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.